News

Echelon Biosciences acquires California Peptide Research

Contributed by admin on April 22, 2014 - 7:53 AM

April 17, 2014 -- Press Release

A NATURAL STEP FOR PEPTIDE RESEARCH

Echelon Biosciences acquires California Peptide Research


Salt Lake City - Echelon Biosciences, Inc. (EBI) announces the acquisition of California Peptide Research, Inc. (CPRI) to offer its line of biochemicals and research peptides, and to further drive innovations in the growing peptide research and development markets.

The primary customers of EBI include pharmaceutical and research and development companies, whose research indicates dramatic growth in the peptide therapeutics market and vast expansion over the next five years.

"The acquisition represents a natural, strategic step for Echelon," said W. Tim Miller, President and CEO of EBI.

According to a report published Mar. 13, 2013 by Transparency Market Research, "...the global peptide therapeutics market was valued at USD 14.1 billion in 2011 and is estimated to reach a market worth USD 25.4 billion in 2018..."

"Peptide therapeutics show neurological applications, including Alzheimer's disease," said Miller, "Along with broader capabilities for developing assays - superior to traditional methods."

CPRI was founded in 1993, and remains a recognized provider of standard, unique and custom peptides for use in medical research, biology and biochemistry, continually maintaining a reputation for reliable and quality products in the peptide research field.

"This will provide Echelon an expanded offering of research reagents to our pharmaceutical and diagnostic customers," said Miller, "As well as incorporate the peptide expertise into our own research and development."

CPRI will relocate operations to the Salt Lake City-based facility of EBI, and join corporate divisions that include Logan, UT-based Frontier Scientific, Inc. and Newark, DE-based Frontier Scientific Services, Inc.

CPRI products will continue to be offered via the CPRI website, additionally via the EBI website and be offered in the near future through Frontier Scientific Services, Inc.

"We are please to have completed the acquisition of California Peptide," said Miller, "This acquisition allows Echelon to marry its strength, credibility and biochemical research expertise with the service and product offerings of CPRI."

About Echelon Biosciences, Inc.

Established in 1997, Echelon Biosciences, Inc. (EBI) aims to further the science of lipid-cell signaling and critical metabolic enzymes through the development of biochemicals, assays and reagents that aid research in the fields of cancer, inflammation, neurobiology and metabolism. In 2007, EBI was acquired by Frontier Scientific, Inc., a recognized provider of boronic acids and porphyrin compounds for application development, and pharmaceutical and industrial research. Frontier Scientific Services, Inc. provides solutions for sample management and other common issues when conducting research -- sample library curation, standardization and re-formatting, compound procurement, storage and distribution, LC/GC-MS analysis and in-sourced staffing. California Peptide Research, Inc. (now) represents the fourth corporate division, whose peptide-based products are used in medical research, biology and biochemistry.

 

ASDI Inc. assets acquired by Frontier Scientific Services Inc.

Contributed by admin on Sep 09, 2011 - 11:53 AM
September 8, 2011 -- Press Release

For Immediate Release

ASDI Inc. assets acquired by Frontier Scientific Services Inc.

September 8th, 2011

Effective September 1st, 2011, Frontier Scientific Services, Inc. (FSSI) has acquired the assets of ASDI.

ASDI has been a recognized leader in providing chemical services to pharmaceutical, industrial, and academic clients. These valuable services now provided by FSSI include:

  • Compound library management to include registration, net inventory capture, material analysis, and reformatting to powder or liquid specifications with distribution to most locations worldwide
  • Sample acquisition – sourcing compound identifiers/structures specified and provided in a client specified format
  • Building Block offering - catalog of high quality, diverse intermediates and building blocks available through an online ordering system, allowing for just-in-time delivery of pre-weighed micro-molar quantities
  • Liquid handling – state-of-the-art, climate controlled capabilities including solvation, plate replication, formatting and transfer
  • Analytical services – in house equipment includes NMR, LC-MS, GC-MS
  • Purification/Reclamation – cost-effective services to recapture pure compound to optimize client time from synthesis to screening

“We are pleased to have completed the acquisition of the assets of ASDI Inc.” said W. Tim Miller, President and CEO of Frontier Scientific. “This will allow the Frontier portfolio of companies to broaden our scope and expand our product and service offerings to our pharmaceutical, government and university customer base. The chemical procurement, library management, and analytical services of ASDI will complement our existing chemical building block and molecular biology product offerings.”

FSSI is private and will be managed as an independent portfolio company of Frontier Scientific Inc.

This transaction allows Frontier Scientific to marry its strength, credibility, and financial stability with the services and product offerings of ASDI. The ASDI name will be transitioned out over the next few months with seamless operations to customers. The entire ASDI catalog will still be available, contact information will remain the same, and the company will stay in the same location with the same address. The legacy of quick and responsive service will be improved with ongoing investments.

About Frontier Scientific Inc. (FSI)
FSI is a premier source of boronic acid and porphyrin compounds and a chemical developer, manufacturer, and custom research service(s) provider to the pharmaceutical, biotechnology, industrial chemical, government, and academic sectors. FSI specializes in boronic acids, porphyrins, phthalocyanines, ionic liquids, dendrimers, heterocycles and many other chemical building blocks. FSI develops compounds for small molecule drug discovery, SAR studies, and lead optimization. FSI provides catalog products with production quantities generally from the milligram to kilogram scale. FSI is a privately held corporation headquartered in Logan, Utah. (www.frontiersci.com)

This acquisition bolsters the late 2007 FSI acquisition of Echelon Biosciences Inc. (EBI), a Utah-based life science company. FSI’s investment in EBI opened the doors for expanded research with the aim to further the science of lipid cell signaling and critical metabolic enzymes, providing new and viable targets for the development of potential drugs and diagnostics for cancer, diabetes, inflammation, infections, and cardiovascular disease. Since 1997, EBI has strengthened its commitment to developing novel assays and reagents for lipid research and beyond. (www.echelon-inc.com)

Although a common management team will guide the portfolio companies of Frontier Scientific Services, Frontier Scientific, and Echelon Biosciences, the companies will be run independently yet will offer common products and services where appropriate to best serve its customers.

Contacts

W. Tim Miller, President and CEO
Frontier Scientific Services, Inc.
(801) 588-0455 ext. 306

Kabana Perkins, General Manager
Frontier Scientific Services, Inc.
(302) 266-6891 ext. 147

Frontier Scientific Services, Inc.
601 Interchange Blvd.
Newark, Delaware 19711
www.frontierssi.com

Advanced Discovery Chemicals